Prices delayed by at least 15 minutes | Print


Novacyt S.A. (NCYT)

EUR1/15TH (CDI)
Sell: 43p|Buy: 45.4p|Change: 0.91 (2.06%)

Open 

45.35p


Previous close 

44.25p


Trade high 

45.95p


Volume 

27,656


Year high 

86.00p


Year low 

35.80p


Dividend yield 

-


Market capitalisation 

£31.90 mn


P/E ratio 

1.19


ISIN 

FR0010397232


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Novacyt S.A.- 0.56
FTSE AIM All Share+ 0.35
More...

Company profile

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202410:30:3445.163212,5215,654.88
28/03/202410:26:2145.72511.43
28/03/202410:16:2943.277522195.64
28/03/202410:09:3143.277514663.19
28/03/202410:03:5043.277510645.87

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.